Abstract��OBJECTIVE To explore the correlation between genetic polymorphism of folylpolyglutamate synthetase (FPGS),plasma concentrations of methotrexate (MTX) and prognosis in patients with acute leukemia. METHODS PCR-restriction fragment length polymophism(PCR-RFLP) was used to detect the genetic polymorphisms of FPGS rs1544105 in ALL patients(n=57) and the control individual(n=31). The plasma concentrations of MTX were measured by high performance liquid chromatography (HPLC) at the times of 24 and 44 h. The association between targeted polymorphisms and MTX concentration-to-dose (C/D) ratios was assessed. According to the result of follow up, survival curve was analyzed. RESULTS Similar frequencies of genotypes and alleles were found at FPGS rs1544105 in healthy subjects and ALL patients. In the genotype of AA, MTX C/D ratio at the time of 24 h was higher than the others (P<0.05).While there was not a significant difference at 44 h(P>0.05). Kaplan-Meier survival analysis showed that median survival time of AA genotype was longer than others. Overall survival(OS) rate was statistically different(P<0.05). CONCLUSION Folylpolyglutamate synthetase (FPGS) genetic polymorphism may be a useful method to predict the effectiveness of methotrexate.
����,������,Ǯ����,��ԭ. Ҷ����۹Ȱ���ϳ�ø�����̬�ԶԼ���Ѫ������������װ��������Ƶ�Ӱ��[J]. �й�ҩѧ��־, 2015, 50(17): 1536-1540.
HUANG Zhen, WANG Ju-xiang, QIAN Jiang-chao, LI Yuan. Influence of Folylpolyglutamate Synthetase Genetic Polymorphism on Treatment of Methotrexate in Acute Lymphocytic Leukemia Patients. Chinese Pharmaceutical Journal, 2015, 50(17): 1536-1540.
MANTADAKIS E,COLE P D,KAMEN B A. High-dose methotrexate in acute lymphoblastic leukemia:Where is the evidence for its continued use [J]. Pharmocotherapy,2005,25(5):748-755.
[2]
HUANG L, TISSING W J, DE J R, et al. Polymorphisms in folate-related genes:Association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia [J]. Leukemia, 2008,22 (9) :1798-1800.
[3]
PANG L, LIU L M, ZHAO L M. Research progress in influence factors of excretion delay of high-dose methotrexate[J]. Chin Pharm J(�й�ҩѧ��־), 2013,48(22):1892-1896 .
[4]
GANGJEE A, JAIN H, KURUP S. Recent advances in classical and non-classicalantifolates as antitumor and antiopportunistic infection agents[J]. Anti-cancer Agents Med Chem, 2007, 7(5):514-542.
[5]
LECLERC G J, MOU C,LECLERC G M,et al.Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia:Implications for combination therapy[J]. Leukemia,2010,24(3):552-562.
[6]
Pediatric Hematology Group of Chinese Medical Association,Editorial Board of Chinese Journal of Pediatrics. Diagnosis and treatment of childhood acute lymphoblastic leukemia (third recension protocol)[J]. Chin J Pediatr(�л�������־),2006,44(5):392-395.
[7]
SHARMA S,DAS M,KUMAR A, et al.Purine biosynthetic pathway genes andmethotrexate response in rheumatoid arthritis patients among north Indians[J]. Pharmacogenet Genom, 2009,19(10):823-828.
[8]
ZENG D X,XIANG F.Determination of methotrexatelevel in plasma by reversed phase high performance liquid chromatography[J]. Herald Med(ҽҩ����),2004, 23(3):194-195.
[9]
SUN W,MA L,HAN Z W, et al.Pharmacokinetics of high-dose methotrexate in the treatment of pediatric lymphocytic leukemia [J]. Chin Pharm J(�й�ҩѧ��־),2002,37(10):768-770.
[10]
IZBICKA E, DIAZ A, STREEPER R, et al. Distinct mechanistic activity prowle ofpralatrexate in comparison to other antifolates in in vitro and in vivo models ofhuman cancers [J].Cancer Chem Pharm, 2009, 64(5):993-999.
[11]
ESTI L, LILAH R, MARLENE A, et al. Loss of folypoly-��-glutamate synthetase activityis a dominant mechanism of resistance to polyglutamaylation-dependent novelantifolates in multiple human leukemia sublines[J].Inter J Cancer,2003,103(5):587-599.
[12]
LECLERC G J,YORK T A,HSIEH K T,et al.Molecular basis for decreased folypoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutatant cell line[J].Leuk Res,2007,31(3):293-299.
[13]
WANG S M, SUN L L, ZENG W X, et al. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia[J].Cancer Chem Pharm, 2014,74(2):283-289.
[14]
SHARMA S, DAS M, KUMAR A, et al. Interaction of genes frominflux-metabolism-efflux pathway and their influence on methotrexate efficacy inrheumatoid arthritis patients among Indians[J].Pharmacogenet Genom,2008, 18(12):1041-1049.
[15]
LIU S G,LI Z G,CUI L,et al. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population[J].Leuk Lymphoma,2011,52(6):1030-1040.
[16]
PANETTA J C, SPARREBOOM A, PUI C H,et al. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells[J]. PLoS Comput Biol, 2010, 6(12):e1001019.
[17]
XU H,ZHANG Y N,KANG X X. The relationship between methylene tetrahydrofolate reductase gene polymorphism and serum concentration of methotrexate in children with acute lymphoblastic leukemia[J]. Chin J Lab Diagn(�й�ʵ�����ѧ),2010 ,14(5):676-679.
[18]
ZHANG H H,YUE L J,CHEN X W. Polymorphism of gamma-glutamy hydrolase and methotrexate sensitiveity[J]. Inter J Pediat(���ʶ���ѧ��־),2011,38(5):497-500.
[19]
LI H,JIANG H. Association between the drug-metabolizing enzyme gene polymorphism and toxicity of methotrexate in childhood acute lymphoblastic leukemia[J]. Inter J Pediat(���ʶ���ѧ��־),2012 ,39(3):274-276.
[20]
SUN L,SHEN Z J. Folylpoly-gamma-glutamate synthetase and anti-tumor drug resistant[J]. Chem Life(�����Ļ�ѧ),2010 ,30(2):299-302.
[21]
STARK M,WICHMAN C,AVIVI I, et al.Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia[J]. Blood,2009,113(18):4362-4369.
2015, Vol. 50 
